Table of Contents
CFOs and pharmacy executives at every 340b covered entity are staring down a radical shift in pharmacy economics. The era of passive savings is dead. It has been replaced by a landscape where manufacturer policies now target the very heart of hospital operations: the in-house pharmacy.
The recent court victory in AHA v. Kennedy blocking HRSA’s initial rebate pilot provided only a brief reprieve. HRSA’s new Request for Information (RFI), with its April 20, 2026 deadline, signals that the push for a “cash-first” model remains a federal priority. This transition would force hospitals to pay full market price upfront and wait months for rebates. It is a liquidity crisis disguised as administrative reform. For an oncology department already operating on razor-thin margins, this delay in capital could be catastrophic for patient access and long-term sustainability.
The Data Trap for 340B Covered Entities
The most immediate threat isn’t coming from Washington, it is coming from manufacturers. Eli Lilly and Novo Nordisk have expanded their data mandates to include in-house pharmacy dispenses. This changes everything. Historically, 340b covered entities only worried about contract pharmacy restrictions. Now, accessing 340B pricing requires granular, claim-level data (CLD) for your internal operations.
Failure to submit this data within 45 days results in an immediate loss of 340B pricing access. This turns your internal pharmacy into a compliance liability overnight. You cannot afford to treat 340B as a siloed pharmacy task anymore. It is an enterprise-wide data integrity initiative. If your EMR and pharmacy systems do not communicate perfectly, your savings will vanish, and your patient advocates will be left without the resources needed to support vulnerable populations.
Redefining 340B Program Eligibility
While 340b program eligibility was traditionally defined by patient volume and DSH percentages, 2026 has introduced a new metric: data maturity. The program is no longer just about who you serve. It is about how well you can prove it in real-time.
Recent Ninth Circuit rulings have opened the door for False Claims Act (FCA) litigation against manufacturers for overcharging. This is a rare piece of good news, but it comes with a catch. To win an Administrative Dispute Resolution (ADR) claim or a lawsuit, a 340b covered entity must possess impeccable, audit-ready data. You cannot recover what you cannot prove. On top of this, the March 31st deadline for the CMS drug acquisition cost survey has put hospital leaders in a bind. Reporting these costs is now tied to future OPPS reimbursement rates. Every data point you submit today impacts your revenue in 2027.
The Path Forward
Audit your Third-Party Administrator (TPA) immediately. Verify that your data feeds from the EMR are capturing every required field for Eli Lilly and Novo Nordisk. Move beyond reactive compliance. Pharmacy and finance teams must align now to build a “single source of truth” for 340B claims.
The window for “business as usual” has closed. In this new era, the margin for error has hit zero. Protect your safety net and your patients by turning your data into a defensive shield.
